Gay, bisexual, and other men who have sex with men (MSM) continue to have disproportionately high burdens of HIV infection in countries of low, middle, and high income in 2016. 4 years after publication of a Lancet Series on MSM and HIV, progress on reducing HIV incidence, expanding sustained access to treatment, and realising human rights gains for MSM remains markedly uneven and fraught with challenges. Incidence densities in MSM are unacceptably high in countries as diverse as China, Kenya, Thailand, the UK, and the USA, with substantial disparities observed in specific communities of MSM including young and minority populations. Although some settings have achieved sufficient coverage of treatment, pre-exposure prophylaxis (PrEP), and human rights protections for sexual and gender minorities to change the trajectory of the HIV epidemic in MSM, these are exceptions. The roll-out of PrEP has been notably slow and coverage nowhere near what will be required for full use of this new preventive approach. Despite progress on issues such as marriage equality and decriminalisation of same-sex behaviour in some countries, there has been a marked increase in anti-gay legislation in many countries, including Nigeria, Russia, and The Gambia. The global epidemic of HIV in MSM is ongoing, and global efforts to address it remain insufficient. This must change if we are ever to truly achieve an AIDS-free generation.

Introduction

In July, 2012, The Lancet published a Series on gay, bisexual, and other men who have sex with men (MSM) and HIV, which was released at the XIX International AIDS Conference in 2012. The Series of comprehensive reviews on epidemiology, prevention, clinical care, health disparities in racial and ethnic minority MSM, community responses, and politics, reported on the widespread severity of MSM HIV epidemics worldwide, and on the limited and insufficient responses for this expanding component of the pandemic. The final paper was a call to action,1 which laid out a research agenda and an ambitious plan for improved programmatic responses for HIV services for MSM. The plan called for action on the areas identified in the Series as essential to curtail HIV epidemics in MSM. The call to action requires responding to the needs of prevention and treatment programmes, and efforts to improve HIV prevention and treatment services, including expanded access to pre-exposure prophylaxis (PrEP) and increased coverage of antiretroviral treatment (ART). The papers in the Series showed that, because of the increased biological susceptibility to HIV infection of MSM and high burden of infection in MSM, the bar for HIV prevention is set high.2 Accordingly, specific goals in the call to action were ambitious: a 20% increase over 2 years in the number of countries that would repeal laws criminalising same-sex sexual practices; and a 40% increase in the number of countries that would add MSM to ongoing HIV surveillance strategies and to national AIDS strategies, with the ultimate goal of adjusting national funding for HIV to be consistent with domestic HIV epidemiology.

Although the response to AIDS has seen important research advances and continued reduction in incidence and expansion of treatment access for those living with HIV, the global epidemic in gay men and other MSM remains severe and is clearly one of the defining challenges ahead in the effort to control the HIV pandemic. The past several years have seen notable progress in the science of HIV prevention, coverage of prevention and treatment programmes, and characterisation of the epidemiology of HIV in MSM. Now, the task is to bring evidence-based and human-rights affirming interventions to scale, while more effectively addressing the stigma that prevents the uptake of HIV prevention and treatment services.

Advances

Policy and programme advances

The call to action paper made several recommendations for policy change, and although there is some progress to report along with increased attention in donors to MSM and key population issues generally (table), important reforms are still needed.3 For example, the paper called for major donors to develop a coordinated strategic plan to address HIV and MSM, but coordination in major donors and programmes remains unstructured and informal. However, some major funders have been slower than expected to advance policy and programmes.

The US President’s Emergency Plan for AIDS Relief (PEPFAR) and the US Department of State under Secretaries Clinton and Kerry have been vocally

---

**Search strategy and selection criteria**

We updated the search done in 2011–12 for the Lancet Series on HIV in men who have sex with men (MSM), focusing on estimates of HIV incidence in MSM in the past 5 years. We searched PubMed and Embase with medical subject heading (MeSH) terms and related keywords “homosexuality, male”[MeSH], “men who have sex with men”[keyword], and “MSM”[keyword], which were cross-referenced with “HIV”[keyword] or human immunodeficiency virus [MeSH], and “incidence”[MeSH]. Only articles published in English between Jan 1, 2007, and Oct 1, 2015, were included.
supportive of lesbian, gay, bisexual, and transgender (LGBT) rights, as have the former (Eric Goosby) and current (Deborah Bix) ambassadors of the PEPFAR programme. Funding for the HIV response in MSM through PEPFAR is gradually improving. In 2012, PEPFAR created a US$20 million Key Populations Challenge Fund, though it has only reached six countries. The new Continuum of HIV Services for Key Populations Affected by HIV (LINKAGES) programme funded by United States Agency for International Development (USAID) will provide a base of $73 million over 5 years to programmes for key populations including MSM. In June, 2016, at the UN High Level Meeting on AIDS, Ambassador Bix announced a new $100 million Key Populations Investment Fund, which will include additional resources for MSM. PEPFAR has called for the targeting of resources to the right places, the right people, at the right time, and PEPFAR guidance to country teams has placed increasing emphasis on activities focused on key populations in annual Country Operating Plans. These activities not only include prevention, care and treatment activities, but also civil society capacity building, stigma and discrimination mitigation activities, and other human rights activities. Further, PEPFAR published Technical Guidance on HIV Prevention for MSM, which addressed many of these key areas.

The Global Fund to Fight AIDS, Tuberculosis, and Malaria’s strategy in relation to Sexual Orientation and Gender Identity and the Global Fund’s most-at-risk populations (MARPs) Reserve Fund, have resulted in some increases in funding and programmes addressing MSM, and country dialogues under the new funding model are expected to advance the response in MSM and other key populations. However, as is well documented in countries of eastern Europe, MSM are too often excluded from the country dialogue, Country Coordinating Mechanisms, and from other planning processes. Even where MSM are represented, the actual extent of their influence is low. As of September, 2015, the Global Fund’s Community, Rights and Gender Special Initiative has influenced is low. As of September, 2015, the Global Fund’s MSM and other key populations programme for HIV grants signed under the New Funding Model is underway.

Public and private sector donors continue to play a crucial role in supporting MSM programmes in low-income and middle-income countries. Notable government donors include Denmark, France, Germany, Ireland, Norway, Sweden, the UK, and the USA. Of concern, several of these countries with progressive approaches to key populations, including Denmark, Norway, and Sweden, have recently reduced their investment in global AIDS. Active foundation donors include the Bill & Melinda Gates Foundation, Elton John AIDS Foundation, the MAC AIDS Fund, Viiv, AIDS

<table>
<thead>
<tr>
<th>Achieved</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major donors develop coordinated strategic plan to address HIV in MSM</td>
<td>No ...</td>
</tr>
<tr>
<td>Report from major donors on their coordinated efforts</td>
<td>No ...</td>
</tr>
<tr>
<td>Donor funds to MSM and HIV work tracked and information made public</td>
<td>No ...</td>
</tr>
<tr>
<td>First report of accountability system</td>
<td>No ...</td>
</tr>
<tr>
<td>Key populations, including MSM, prioritised in new funding announcements</td>
<td>Yes CDC, NIH, PEPFAR, USAID, GFATM, and amfAR</td>
</tr>
<tr>
<td>Worldwide targets set for expanding service delivery and overcoming legal and policy barriers to health services with external validation</td>
<td>No ...</td>
</tr>
<tr>
<td>Targets met for expansion of service coverage and overcoming of legal and policy barriers</td>
<td>No ...</td>
</tr>
<tr>
<td>Accountability system in place to track MSM-related or HIV-related legal and policy change and service delivery</td>
<td>No ...</td>
</tr>
<tr>
<td>Evidence of increased funding to address HIV in MSM</td>
<td>Yes CDC, NIH, PEPFAR, USAID, GFATM, and amfAR</td>
</tr>
<tr>
<td>Operational research on MSM and HIV services launched</td>
<td>Yes PEPFAR, USAID SOAR Operations Research</td>
</tr>
<tr>
<td>Demonstration projects on MSM use of PrEP and comprehensive prevention (including treatment as prevention) launched</td>
<td>Yes Many PrEP demonstration projects underway</td>
</tr>
<tr>
<td>MSM representatives on all country HIV planning bodies, including Global Fund Country Coordinating Mechanisms</td>
<td>No However, there is evidence of increased MSM organisation participation on HIV planning bodies</td>
</tr>
<tr>
<td>Evidence of increased support to civil society for work to repeal laws and policies that inhibit access to care and enable stigma and discrimination, and to provide needed services and advocacy</td>
<td>Yes Notably, amfAR and the Robert Carr Civil Society Networks Fund are providing financial and technical support to community organisations working with gay men, other men who have sex with men, and transgender individuals</td>
</tr>
<tr>
<td>20% more countries announce removal or repeal of laws that criminalise same-sex sexual behaviour</td>
<td>No 1% increase in the number of countries which criminalise same-sex sexual behaviour (India, Nigeria, Russia, The Gambia, and Uganda)</td>
</tr>
<tr>
<td>40% more countries include MSM in HIV epidemiological tracking</td>
<td>No 73 countries did not report data on HIV prevalence in MSM in 2013</td>
</tr>
<tr>
<td>40% more countries adjust funding allocations to be consistent with domestic epidemiology and MSM</td>
<td>No ...</td>
</tr>
<tr>
<td>40% more countries include MSM in their national AIDS strategies</td>
<td>No ...</td>
</tr>
</tbody>
</table>
Review

The Robert Carr Civil Society Networks Fund has emerged as an important funder of worldwide and regional networks working to advance the response in inadequately addressed populations, including gay men and other MSM. Since 2013, the fund has invested more than $18 million in civil society organisations and the networks that facilitate their coordination.

Scientific advances

The greatest scientific advances since 2012 have been in prevention methods involving antiretroviral drugs. Consistent findings of the high efficacy and effectiveness of oral PrEP with tenofovir and emtricitabine for primary prevention of HIV infection in MSM have altered the prevention landscape for gay and other MSM. The PROUD effectiveness study, done in sexually transmitted infection (STI) clinics in the UK was particularly important because it was the first open-label PrEP study to show high efficacy, 86% (90% CI 64–96%) in a real-world setting. This put to rest the concerns that MSM at greatest risk who accessed PrEP would be insufficiently adherent to make it an effective public health intervention. Given the open-label status of the study, it provided evidence that STI incidence did not increase in people using PrEP; rates of STIs were similarly high both in men randomly assigned to immediate and in those assigned delayed access to PrEP.

Subsequent implementation studies of PrEP use in MSM have yielded consistently impressive results, notably the report from Volk and colleagues, which presented clinical findings from over 675 MSM prescribed PrEP through the Kaiser-Permanente programme in San Francisco. Not a single incident HIV infection occurred in these men in 2·5 years of follow-up, despite high and sustained prevalence of other STIs; these findings show that real-world effectiveness of PrEP for MSM is substantially higher than the efficacy reported from intention-to-treat analyses in early trials. The PROUD and Volk and colleagues’ studies also emphasise the importance of using PrEP as part of a comprehensive sexual health package (ie, engaging otherwise healthy MSM to come in for routine clinical assessments, adherence monitoring, and STI screening). The increased frequency of STI screening might initially be associated with increased infection detection, but in the long run, could have a beneficial effect of identifying prevalent infections sooner. If implemented, this treatment approach is a potential major change in the prevalent infections sooner. If implemented, this could have a beneficial effect of identifying prevalent infections sooner.

Consistent findings of the high efficacy and effectiveness of oral PrEP with tenofovir and emtricitabine for primary prevention of HIV infection in MSM have altered the prevention landscape for gay and other MSM. The PROUD effectiveness study, done in sexually transmitted infection (STI) clinics in the UK was particularly important because it was the first open-label PrEP study to show high efficacy, 86% (90% CI 64–96%) in a real-world setting. This put to rest the concerns that MSM at greatest risk who accessed PrEP would be insufficiently adherent to make it an effective public health intervention. Given the open-label status of the study, it provided evidence that STI incidence did not increase in people using PrEP; rates of STIs were similarly high both in men randomly assigned to immediate and in those assigned delayed access to PrEP.

Subsequent implementation studies of PrEP use in MSM have yielded consistently impressive results, notably the report from Volk and colleagues, which presented clinical findings from over 675 MSM prescribed PrEP through the Kaiser-Permanente programme in San Francisco. Not a single incident HIV infection occurred in these men in 2·5 years of follow-up, despite high and sustained prevalence of other STIs; these findings show that real-world effectiveness of PrEP for MSM is substantially higher than the efficacy reported from intention-to-treat analyses in early trials. The PROUD and Volk and colleagues’ studies also emphasise the importance of using PrEP as part of a comprehensive sexual health package (ie, engaging otherwise healthy MSM to come in for routine clinical assessments, adherence monitoring, and STI screening). The increased frequency of STI screening might initially be associated with increased infection detection, but in the long run, could have a beneficial effect of identifying prevalent infections sooner. If implemented, this treatment approach is a potential major change in the widespread prevalence of other STIs; these findings show that real-world effectiveness of PrEP for MSM is substantially higher than the efficacy reported from intention-to-treat analyses in early trials.

The PROUD and Volk and colleagues’ studies also emphasise the importance of using PrEP as part of a comprehensive sexual health package (ie, engaging otherwise healthy MSM to come in for routine clinical assessments, adherence monitoring, and STI screening). The increased frequency of STI screening might initially be associated with increased infection detection, but in the long run, could have a beneficial effect of identifying prevalent infections sooner. If implemented, this treatment approach is a potential major change in the widespread prevalence of other STIs; these findings show that real-world effectiveness of PrEP for MSM is substantially higher than the efficacy reported from intention-to-treat analyses in early trials.
and other MSM continue to face barriers to HIV testing and treatment worldwide. For example, a study\(^6\) in India found that only 30% of a cohort of 1146 MSM living with HIV reported being aware of their HIV-positive status, 23% were linked to care, 16% had started ART, 16% were receiving ART at the time, and only 10% had suppressed viral loads.

Taken together, these realities provide exciting new opportunities to address the HIV epidemic in gay men and other MSM alongside major coverage challenges that must be overcome. According to data in the 2012 Lancet Series and subsequent modelling studies,\(^6\) decreasing HIV incidence will require countries to achieve 40–50% coverage of multiple HIV prevention interventions, including PrEP, condom and condom compatible lubricant promotion and effective distribution, and increased HIV testing frequency by using new methods such as self-testing and couples testing for HIV. PrEP and early initiation of treatment provide new prevention approaches with ever expanding evidence for effectiveness. But PrEP is only being implemented in six countries as of June, 2016, and we have stable or growing HIV epidemics in MSM, which shows the failure of prevention programmes in implementing PrEP and getting sufficient HIV-infected MSM into stable care. The barriers to MSM receiving PrEP are importantly related to the challenges of poor access to effective ART for MSM living with HIV in settings where MSM are stigmatised, criminalised, or both. In both cases, improving prevention and treatment outcomes for MSM will require increased availability of culturally competent care, improvement of retention in HIV or PrEP care, support of men living with HIV to achieve viral suppression, and support of men on PrEP to achieve suitable adherence to PrEP.

The implementation of PrEP, of early ART for MSM living with HIV, and of combination approaches including these crucial methods in addition to condom availability and increased HIV testing clearly requires supportive environments for MSM, specifically environments in which men can access prevention services safely. Such environments can be promoted through policy and programme changes by government at multiple levels and by programme implementers. Global normative bodies, such as WHO, and donors need to insist on and incentivise safe environments for delivery of health services to MSM. We will consider challenges with respect to (criminalisation), other discriminatory laws and policies, and perpetuation of stereotypes of gay and bisexual men that are hindering epidemic control.

**Implementation advances**

The expansion of research on approaches to HIV prevention, treatment, and care in MSM has been a high point of the past 2 years. In July, 2012, PEPFAR announced the creation of a $15 million Key Populations Implementation Science Fund,\(^2\) and these funds are now supporting studies in key populations (including MSM) in 12 countries. The new USAID Supporting Operational AIDS Research (SOAR) Operations Research programme will make substantial new funds available, including for research in MSM.\(^3\) The Global Fund supports operational research to address programmatic issues in grant implementation, including for key populations.\(^4\) However, the Global Fund Secretariat does not have a mechanism to systematically track and monitor its investment in this area. The new US National Institutes of Health (NIH) priority research areas for HIV include implementation research methods, which are especially relevant to the study of new opportunities to improve coverage of antiretroviral-based HIV prevention and treatment methods.\(^5\) amFAR redesigned its gay men, other men who have sex with men, and

Figure: Global estimates of HIV incidence in men who have sex with men by country in 1995–2015

(A) High-income countries. (B) Low-income and middle-income countries. Country income classification based on World Bank Country Classifications; dashed lines represent incidence data that are not disaggregated by year.

*Two estimates for Thailand were from the same study, but were estimated with different analyses.

www.thelancet.com Vol 388 July 9, 2016 201
transgender individuals (GMT) initiative in 2014 to focus on MSM-related implementation science research.\textsuperscript{26} Treatment as prevention for MSM has also been implemented slowly in low-income and middle-income countries; as of March, 2014, only seven studies were investigating test-and-treat approaches in MSM.

**Challenges**

**Political successes and challenges**

Stigma and discrimination are not merely broad cultural forces, but are operationalised through discriminatory policy and political actions, which are modifiable and should be modified. The period 2012–14 has been a watershed period for LGBT rights in several countries, notably Argentina, France, Finland, Spain, the UK, and the USA, with historic advances in marriage equality and civil rights.\textsuperscript{27} In 2015, Mozambique decriminalised same-sex sexual behaviour.\textsuperscript{28} The UN, led by Secretary General Ban Ki-moon, continued to be a worldwide leader in LGBT equality. However, the worldwide status of laws and policies criminalising same-sex behaviour or furthering discrimination and social exclusion has been broadly discouraging. In 2013, the Indian Supreme Court reversed an earlier New Delhi High Court decision and reinstated the colonial era statute 377, again criminalising same-sex behaviour between consenting adults in India.\textsuperscript{29} This decision was immediately condemned by India’s LGBT community as a setback for HIV programmes and for sexual and gender minority rights.\textsuperscript{30} Also in 2013, the Russian Government passed, and President Putin signed into law, a highly discriminatory anti-homosexuality propaganda law, which led to the closure of HIV information websites for gay men and sharply restricted non-governmental organisation activities and services.\textsuperscript{31} The Russian Government has been pressing its views on other governments it seeks to influence, and a wave of similar repressive laws have been passed or are being debated in former Soviet Union states.\textsuperscript{32}

In early 2014, Goodluck Jonathan, then President of Nigeria, signed a law criminalising same-sex marriage, which has provisions that will restrict access to services and freedom of assembly, and will take a range of rights guaranteed to all citizens under the Nigerian Constitution from Nigerian LGBT people and anyone working with them.\textsuperscript{33} Arrests of LGBT activists were reportedly underway in Nigeria within days of the passing of the law. During the same time, the Ugandan President signed an anti-homosexuality bill (same-sex behaviour was already criminalised in Uganda), which would make provision of information and services to MSM in Uganda a crime.\textsuperscript{34} In April, 2014, Ugandan Government forces raided the Makerere University Walter Reed Project, which provides HIV treatment and sponsors HIV research. One government official said the raid occurred because the site was “training youths in homosexuality”.\textsuperscript{35} The Ugandan law was suspended on technical grounds in 2014, but could be reinstated. The Gambia passed legislation imposing life sentences for some homosexual acts.\textsuperscript{36} All five countries mentioned above have substantial HIV epidemics in MSM, and these policies must be counted as highly noteworthy setbacks to global AIDS control and research.\textsuperscript{37}

Although India, Nigeria, Russia, and The Gambia are highly diverse countries with different cultural histories, Russia and Uganda share at least one common theme in their embrace of discriminatory laws and policies toward LGBT citizens: the active engagement of US evangelical conservatives in repressive policy development.\textsuperscript{38} Among them is the Reverend Scott Lively, a US evangelical activist, who has been indicted for crimes against humanity for these activities by a court in Massachusetts, in a case filed by Sexual Minorities Uganda (SMUG).\textsuperscript{39} Elsewhere, governments and scientists perpetuate outdated and inaccurate stereotypes about MSM, which divert attention from needed conversations about how to make the best use of advances in prevention technologies, such as PrEP. For example, China’s National Centre for AIDS/STD Control and Prevention suggested that the rise in HIV in young MSM (aged 18–26 years), which has also been observed in several other countries, is related to older MSM (older than 26 years) seeking students as sex partners.\textsuperscript{40} The president of a large US HIV health-care service organisation characterised PrEP as a “party drug”.\textsuperscript{41} In a letter to *The Lancet HIV*\textsuperscript{42} Dutch academics argue that PrEP implementation should be delayed to allow for discussion of issues, such as personal responsibility for condom use. We recall no such delays for debate of personal responsibility for condoms use in the implementation of medical male circumcision which, after the third randomised study showing its efficacy, had achieved broad consensus and substantial funding, international standards, and programme assessment for scale-up.\textsuperscript{43} Although groups of very high-risk MSM have specialised prevention needs,\textsuperscript{44} the 2012 *Lancet* Series highlighted that persistent epidemics of HIV in MSM are not, overall, driven by promiscuity or an absence of personal responsibility.\textsuperscript{45} Blaming MSM for their biological susceptibility to HIV infection and transmission serves only as a distraction from the discussion of societal responsibility to make effective prevention methods available to people who would benefit most from these methods.

**Data findings and gaps**

A major part of the problem is that data crucial to understanding HIV epidemics in MSM, and the programmatic response to these epidemics, are insufficient. The call to action identified the need for more countries to include MSM in their HIV epidemiological surveys and to adjust funding allocations to be more consistent with domestic HIV epidemiology, including for MSM.\textsuperscript{1} Inclusion of MSM in epidemiology has improved substantially in the past 5 years, but work remains to improve data and use it effectively in the design of programmes along the HIV care continuum.
The Global Fund tracks HIV prevalence, behaviour, and service coverage with reports of core indicators in its performance framework. As part of its corporate key performance indicators, the Global Fund reports the number of countries with nationally adequate size estimation for key populations. In 2014, 38 countries had nationally adequate estimates for all key populations with an estimated 81 countries having estimates for MSM, based on the joint Global Fund–UNAIDS–WHO review of all existing data. Data from these 81 countries are not representative of all other countries; data from eight countries include data only from the capital city, and data from 17 countries include data from other major cities.46

A 2015 assessment of the availability and quality of size estimations of key population groups found that 41 of 140 countries assessed have not reported any estimates since 2010. The analysis concluded that size estimates for female sex workers, MSM, people who inject drugs, and transgender women are increasingly available, but are insufficient for design, implementation, and evaluation of programmes for these groups in 50% of the countries assessed. Although new methods for the estimation of population size for key populations are emerging, population size estimation faces operational challenges because size estimation methods are logistically difficult to use and often need implementation of multiple methods to improve the precision of estimates.46

UNAIDS tracks HIV prevalence in MSM worldwide through the Global AIDS Response Progress Reports (GARPR) system. In July, 2015, UNAIDS reported that, “globally, HIV prevalence in men who have sex with men appears to be stable, with small peaks reported from the Caribbean and eastern Europe and central Asia”.47

Progress has also been made on epidemiology in some key countries. The US CDC is supporting epidemiological assessments in several countries, and the Bill & Melinda Gates Foundation is funding extensive epidemiology in China, including in MSM. Notable published epidemiological work over the past 2 years includes a pilot cohort study of MSM in Dakar, Senegal, in which a cumulative HIV prevalence of 47-2% and an annual HIV incidence of 16% were reported.48 A mixed methods research study in Malawi identified HIV prevalence among MSM at 15-4%, with 91% of those living with HIV unaware of their status.49 The prevalence of HIV in MSM in sub-Saharan Africa is estimated to be 18.2%. Results from drug resistance testing in a cohort of MSM in Jamaica showed that the prevalence of HIV drug resistance was 28%, which emphasises the importance of genotyping methods to enable effective delivery of HIV treatment.

A 2014 survey of HIV epidemiological data related to MSM observed that HIV surveillance in generalised HIV epidemics has generally focused on average-risk, reproductive-age adults with little attention paid to key population groups, such as MSM. The survey found a high incidence of HIV in MSM in many countries, even as the incidence seems to be decreasing in general population groups in many parts of the world. Similarly, re-emergence of other sexually transmitted infections in MSM has been reported, which suggests ongoing vulnerability to HIV and that co-infections potentially increase susceptibility to HIV infections.50-54

Research gaps and agenda

In August, 2015, the US NIH released new HIV/AIDS research priorities and guidelines for the allocation of AIDS research investments. These new priorities will guide the future of NIH-funded HIV research, including research in MSM. Research topics were prioritised into high, medium, and low priority areas (panel 1). Gaps in knowledge specific to HIV prevention in MSM need to be addressed to optimise the potential efficacy of scientific insights from the past 5 years (panel 2).
Panel 2: Gaps in prevention research regarding MSM

**Epidemiological**
- New technologies to assess HIV incidence to detect rapidly changing patterns of spread
- Assessments of emerging epidemics in key subpopulations (eg, male sex workers)
- Refined understanding of social and sexual networks
- Improved understanding of the use of respondent driven sampling to map networks and obtain improvement assessments of patterns of HIV spread
- Use of phylogenetic analyses to detect patterns of HIV spread
- Improved understanding of the roles of assortative mixing in generating concentrated epidemics

**Social or structural**
- Improved understanding of the role of poverty in HIV transmission in MSM
- Improved understanding of the role of social and structural homophobia in HIV transmission in MSM
- Development and assessment of interventions that address poverty, food insecurity, and housing instability in MSM
- Development and assessment of interventions that address social and structural homophobia experienced by MSM
- Assessment of the role of economic and other incentives in decreasing HIV transmission in at-risk and HIV-infected MSM

**Biobehavioural**
- Improved interventions to address the role of depression and other emotional challenges in HIV risk-taking behaviours
- Integration of counselling-oriented and pharmacotherapy interventions to address the role of substance use disorders in HIV risk-taking
- Increased understanding of best practices to support MSM couples’ relationships, and to enhance serostatus disclosure and protected sex (eg, condoms, PrEP, or both)
- Improved interventions to enable MSM to understand their HIV risks and to take appropriate actions to decrease transmission or acquisition risk
- Development of innovative web-based platforms (eg, websites, mobile apps, games) that enhance health-promoting behaviour in MSM
- Improved real-time drug monitoring tests to assess PrEP adherence
- Improved understanding of the role of genital tract milieu factors (eg, sexually transmitted infections, sexual trauma, and other causes of inflammation on HIV transmission and acquisition)
- Assessment of new chemoprophylactic approaches, including injectable antiretrovirals, infusible monoclonal antibodies, and topical lubricants and douches

**Implementation science**
- Development of best practice guidance for HIV testing of MSM, including self-testing, testing in high-risk venues (eg, bars, saunas), and couples testing
- Development of best practice guidance for the provision of clinical care for HIV-infected MSM
- Development of best practice guidance for the provision of PrEP for at-risk, HIV-uninfected MSM
- Assessment of best practices for training clinicians and health-care systems in the provision of culturally appropriate services for MSM
- Assessment of the impact of interventions to decrease structural and social homophobia on local health-care systems, communities, and key affected populations

Although all of these topical areas are relevant, several are of particular importance.

Because MSM have the highest HIV incidence in the USA, and high incidence was seen in many MSM epidemics worldwide in 2015, the first research priority, reducing incidence, must clearly be among the highest priorities for the HIV response overall. With daily oral PrEP showing such consistent effectiveness, the implementation of this new intervention is an urgent public health priority. New dosing regimens, new agents and formulations, such as longer-acting and injectable PrEP, and leveraging digital approaches to support adherence are all active areas of research.

Universal access to HIV treatment, including couples-based strategies for discordant couples and seek, test, treat strategies are an important research area for MSM epidemics, because the data on the effectiveness of treatment for prevention in high transmission MSM networks is quite scarce. The landmark HPTN 052 trial had too few same-sex male couples for evaluation of efficacy, although data from the Partners and Opposites Attract studies are promising. However, many new HIV infections occur in the setting of casual relationships and high-risk sexualised settings (eg, in bath houses or meetings arranged online or through mobile phone applications), so new research regarding the best ways to increase testing uptake and linkage to care for MSM are important research priorities.

Testing innovations are an important area of implementation research for MSM. In highly stigmatising environments and settings where homosexuality is still criminalised, self-testing and other decentralised testing approaches could help MSM ascertain their HIV status in safety and dignity. Because PrEP and treatment as prevention are HIV status-dependent interventions, these advances have only heightened the need for regular HIV testing in MSM.

Cost-effectiveness analyses done in the USA have found that regular HIV testing (every 6 months or quarterly) for MSM was cost-effective and could be cost-saving, which provides justification for increased HIV testing. Additionally, because of the high level of infectiousness associated with acute HIV infection, which is often asymptomatic, studies of new assays and testing algorithms are needed.

There are also areas of HIV research that are now arguably of lower priority. Stand-alone behavioural interventions focused on behaviour change, reducing numbers of partners, or raising awareness of the risks of HIV infection have shown little efficacy in reducing rates of new HIV infections, and will not be fundable, by the USA at least, in the new NIH priorities (panel I). Social, behavioural, and structural research efforts that support new antiretroviral based prevention methods (eg, implementation research approaches aimed at improving clinical and prevention outcomes for MSM.
in real-world settings) are clearly high priority research areas.\textsuperscript{26}

Conclusions

Research reported in the \textit{Lancet} Series and subsequent studies provide hope that with a strategic combination of scaled up ART, PrEP, condom and condom-compatible lubricant availability, HIV testing, and other interventions, the HIV epidemics in MSM can be slowed and eventually turned around. Yet, even with substantial advances in the past 5 years, the world is still failing to implement a comprehensive plan of action to use available interventions at scale to address the serious and growing HIV epidemics in MSM. The call to action from 2012 suggested creation of global and national targets for HIV service delivery to MSM in other key population groups.\textsuperscript{1} UNAIDS’ new global targets include 90% coverage of tailored prevention interventions to key populations worldwide by 2020. In September, 2015, PEPFAR set global targets for treatment, voluntary medical male circumcision, and reduction of incidence in adolescent girls and young women, but targets for key population groups were not included. The new $100 million PEPFAR key populations initiative is an important and welcome opportunity to expand access to services, but to reach the scale necessary to have an impact on public health in MSM epidemics will require markedly increased investments in overall national programmes.

Greater investment in civil society groups to provide services and advocate better policy was identified as a priority in the call to action and should remain so. The UNAIDS–\textit{Lancet} Commission Defeating AIDS—advancing global health also called for investment in activism as a worldwide public good.\textsuperscript{57} Since our original paper,\textsuperscript{1} the Robert Carr Civil Society Networks Fund has started to provide much needed resources to civil society groups,\textsuperscript{5} but resources in this area remain inadequate. Increased attention and investment in supporting removal of discriminatory laws and establishment of safer and more equitable environments for gay men and other MSM must also be a priority.

MSM are overburdened and under-resourced in the global HIV response. Despite overwhelming scientific evidence supporting the need for expanded funding, access to services, and policy reform, insufficient progress is being made in the prevention and treatment of HIV in these men and their communities. We can do better, and we must if we are to have any hope of success in controlling HIV spread worldwide.

Contributors

CB conceptualised the overall manuscript and wrote the introduction and discussion. ALW reviewed and analysed the epidemiological data and wrote the epidemiology section. CC, SDB, ETR, KHM, PSS, and ALW all contributed to sections of the manuscript. EK, MK, GT, JS, and OR contributed to the policy sections and revised the manuscript.

Declaration of interests

We declare no competing interests.

Acknowledgments

CB has received grants from Centre for AIDS Research, Johns Hopkins University, and US National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID; F30A1094189). KHM has received grants from Harvard University Center for AIDS Research. The views or opinions expressed in this paper are those of the authors and not of UNAIDS.

References


21 Grulich A, Bavinton BR, Jin F, et al. HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. Conference on Retroviruses and Opporuntistic Infections; Seattle, WA; Feb 23–26, 2015. 109LB.


